Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | Polypeptide deformylase 1 | 0.1017 | 0 | 0.5 |
Trypanosoma cruzi | Peptide deformylase 2, putative | 0.1017 | 0 | 0.5 |
Trypanosoma cruzi | Peptide deformylase 2, putative | 0.1017 | 0 | 0.5 |
Plasmodium falciparum | peptide deformylase | 0.2664 | 1 | 0.5 |
Trypanosoma cruzi | polypeptide deformylase-like protein, putative | 0.1017 | 0 | 0.5 |
Leishmania major | polypeptide deformylase-like protein, putative | 0.1017 | 0 | 0.5 |
Plasmodium vivax | peptide deformylase, putative | 0.2664 | 1 | 0.5 |
Mycobacterium tuberculosis | Probable polypeptide deformylase Def (PDF) (formylmethionine deformylase) | 0.2664 | 1 | 0.5 |
Mycobacterium leprae | PROBABLE POLYPEPTIDE DEFORMYLASE DEF (PDF) (FORMYLMETHIONINE DEFORMYLASE) | 0.2664 | 1 | 0.5 |
Treponema pallidum | polypeptide deformylase (def) | 0.2664 | 1 | 0.5 |
Mycobacterium ulcerans | peptide deformylase | 0.2664 | 1 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | peptide deformylase | 0.2664 | 1 | 0.5 |
Toxoplasma gondii | hypothetical protein | 0.2664 | 1 | 0.5 |
Trypanosoma brucei | Peptide deformylase 2 | 0.1017 | 0 | 0.5 |
Trypanosoma cruzi | polypeptide deformylase-like protein, putative | 0.1017 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | 0 | Cytotoxicity against A431cells | ChEMBL. | 16509573 |
Activity (functional) | 0 | Cytotoxicity against 8701-BC cells | ChEMBL. | 16509573 |
IC50 (functional) | 0 | Antiproliferative activity against 8701-BC cells at 100 uM | ChEMBL. | 16509573 |
IC50 (functional) | = 28.2 uM | Antiproliferative activity against A431 cells | ChEMBL. | 16509573 |
IC50 (functional) | = 28.2 uM | Antiproliferative activity against A431 cells | ChEMBL. | 16509573 |
Ki (binding) | Inhibitory activity against Src in cell free assay | ChEMBL. | 16509573 | |
Ki (binding) | 0 | Inhibitory activity against Src in cell free assay | ChEMBL. | 16509573 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.